And Weldon gets more credit for those new drugs than the average company chief, because much of that productivity came not so much from research as from mergers and acquisitions. Purchases of companies like Alza (maker of pain-relief patches), Tibotec (HIV drugs) and Cougar (the prostate cancer drug Zytiga) have helped keep J&J’s earnings growing. Buying future growth is probably a J&J chief’s main job, and Weldon did it fairly well.